Latest: FDA Approves New Biosimilar for Oncology Treatment

Alzheimer Vaccine ABvac40 Shows Potential to Slow Cognitive Decline in Phase 2 Study

by Neurology Live

13 September, 2025

0 Mins

Data presented at AAIC 2025 from a phase 2 study suggest that ABvac40 may slow cognitive decline in patients with Alzheimer disease, particularly among those who developed higher antibody levels.

Tags:

Author

Neurology Live

EHR or PM: How Having Both Can Help Your Practice’s Bottom Line

Would regenerative treatments help an MCL tear heal faster?

📢

300x250 Banner

Alzheimer Vaccine ABvac40 Shows Potential to Slow Cognitive Decline in Phase 2 Study

Tags:

Neurology Live

EHR or PM: How Having Both Can Help Your Practice’s Bottom Line

Would regenerative treatments help an MCL tear heal faster?

Recent Content

COPD Biologics: Early Treatment Insights

Antihypertensive Medication Guidelines

Juvenile Arthritis Care Transition